NEW YORK, April 15 - BioForce Nanosciences of Ames, Iowa, has received a $500,000 Phase I SBIR grant from the National Institute of Diabetes, Digestive, and Kidney diseases to build an antibody nanoarray for diagnostic tests using small sample volumes, the company said today.
This award, "Protein Nanoarray for Cytokine Profiling in Mouse Models", is one of many SBIR grants that BioForce has received. Last July, the company was awarded a Phase II grant to further develop its nanoarray technology.
The company also has a collaboration with the NCI-FDA clinical proteomics program to develop nanoarrays. BioForce can currently fit a thousand spots within the space of a single ordinary microarrays spot.
Under this grant, the company will develop nanoarrays for protein profiling of cytokine biomarkers in diabetes, progressive renal failure, inflammatory bowel disease, and other kidney and digestive system diseases.